©The Author(s) 2026.
World J Transplant. Mar 18, 2026; 16(1): 112811
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.112811
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.112811
Table 3 Summary of metabolic effects and mechanisms of common
| Immunosuppressant | Major metabolic effects | Proposed mechanisms | Ref. |
| Glucocorticoids | Hyperphagia, central adiposity, insulin resistance | ↑ Appetite via central regulation; ↓ adiponectin, ↑ leptin resistance | [11] |
| Tacrolimus (CNI) | Impaired glucose tolerance, β-cell apoptosis | Inhibition of PI3K/Akt/mTOR; microbiome alterations | [15] |
| Cyclosporine (CNI) | Dyslipidemia, insulin resistance | Mitochondrial dysfunction, oxidative stress | [18] |
| Mycophenolate Mofetil | Dyslipidemia | Synergistic effects when combined with steroids/CNIs | [18] |
| Azathioprine | Less studied; associated with lipid alterations | Likely indirect or combined effects | [18] |
- Citation: Chen KR, Wu LZ, Huang YN, Zhuang SY, Chen ZY, Xu B, Xu TC. Pathogenic analysis of post-transplantation obesity: A comprehensive systematic review. World J Transplant 2026; 16(1): 112811
- URL: https://www.wjgnet.com/2220-3230/full/v16/i1/112811.htm
- DOI: https://dx.doi.org/10.5500/wjt.v16.i1.112811